AMNEAL PHARMACEUTICALS, INC. (AMRX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
35/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinAMRX / S&P 39.26% / 15.20% |
LoseAMRX / S&P 9.28% / 15.00% |
WinAMRX / S&P 4800.00% / 50.40% |
| 2026-Q11/3 |
WinAMRX / S&P -1.35% / -4.33% |
LoseAMRX / S&P 7.62% / 11.30% |
LoseAMRX / S&P -1050.00% / 27.70% |
| 2025-Q41/3 |
WinAMRX / S&P 25.87% / 2.65% |
LoseAMRX / S&P 8.05% / 9.00% |
LoseAMRX / S&P -160.53% / 13.40% |
| 2025-Q32/3 |
WinAMRX / S&P 23.73% / 8.12% |
WinAMRX / S&P 9.50% / 4.61% |
LoseAMRX / S&P -102.35% / 13.45% |
| 2025-Q21/3 |
LoseAMRX / S&P -3.46% / 10.94% |
WinAMRX / S&P 9.81% / 4.83% |
LoseAMRX / S&P -101.27% / 10.63% |
| 2025-Q12/3 |
WinAMRX / S&P 5.81% / -4.27% |
WinAMRX / S&P 13.42% / 4.98% |
LoseAMRX / S&P -94.52% / 10.57% |
| 2024-Q41/3 |
LoseAMRX / S&P -4.81% / 2.41% |
WinAMRX / S&P 16.73% / 5.25% |
LoseAMRX / S&P -20.83% / 6.15% |
| 2024-Q32/3 |
WinAMRX / S&P 31.02% / 5.89% |
WinAMRX / S&P 12.32% / 5.89% |
LoseAMRX / S&P -1516.67% / 6.11% |
| 2024-Q23/3 |
WinAMRX / S&P 4.79% / 4.28% |
WinAMRX / S&P 12.37% / 5.38% |
WinAMRX / S&P 3850.00% / 5.12% |
| 2024-Q11/3 |
LoseAMRX / S&P -0.16% / 10.56% |
WinAMRX / S&P 9.82% / 5.71% |
LoseAMRX / S&P -18.89% / 5.59% |
| 2023-Q42/3 |
WinAMRX / S&P 43.84% / 11.69% |
WinAMRX / S&P 8.20% / 6.81% |
LoseAMRX / S&P -44.19% / 7.78% |
| 2023-Q32/3 |
WinAMRX / S&P 36.13% / -3.27% |
WinAMRX / S&P 11.54% / 7.52% |
LoseAMRX / S&P -106.90% / -5.03% |
| 2023-Q21/3 |
WinAMRX / S&P 123.02% / 8.74% |
LoseAMRX / S&P 8.92% / 9.50% |
LoseAMRX / S&P -97.73% / -8.57% |
| 2023-Q10/3 |
LoseAMRX / S&P -30.15% / 7.50% |
LoseAMRX / S&P 8.29% / 10.77% |
LoseAMRX / S&P -4600.00% / -15.69% |
| 2022-Q40/3 |
LoseAMRX / S&P -1.49% / 7.56% |
LoseAMRX / S&P 5.67% / 11.88% |
LoseAMRX / S&P -1328.57% / -17.99% |
| 2022-Q30/3 |
LoseAMRX / S&P -36.48% / -4.88% |
LoseAMRX / S&P 3.51% / 13.47% |
LoseAMRX / S&P -1066.67% / -1.41% |
| 2022-Q20/3 |
LoseAMRX / S&P -23.74% / -16.10% |
LoseAMRX / S&P 3.16% / 13.71% |
LoseAMRX / S&P -1566.67% / 11.04% |
| 2022-Q10/3 |
LoseAMRX / S&P -12.94% / -4.60% |
LoseAMRX / S&P 5.59% / 15.97% |
LoseAMRX / S&P -116.67% / 42.23% |
| 2021-Q40/3 |
LoseAMRX / S&P -10.30% / 11.03% |
LoseAMRX / S&P 5.08% / 15.00% |
LoseAMRX / S&P -88.71% / 96.40% |
| 2021-Q31/3 |
WinAMRX / S&P 4.30% / 0.58% |
LoseAMRX / S&P 9.95% / 10.77% |
LoseAMRX / S&P -80.43% / 69.42% |
| 2021-Q21/3 |
LoseAMRX / S&P -23.92% / 8.55% |
WinAMRX / S&P 18.33% / 6.58% |
LoseAMRX / S&P -103.97% / 51.81% |
| 2021-Q12/3 |
WinAMRX / S&P 47.26% / 6.17% |
WinAMRX / S&P 18.36% / -1.06% |
LoseAMRX / S&P -92.31% / 7.39% |
| 2020-Q42/3 |
WinAMRX / S&P 17.78% / 12.15% |
WinAMRX / S&P 22.51% / -3.72% |
LoseAMRX / S&P -122.88% / -33.42% |
| 2020-Q31/3 |
LoseAMRX / S&P -18.49% / 8.93% |
WinAMRX / S&P 8.88% / -2.04% |
LoseAMRX / S&P -117.76% / -27.10% |
| 2020-Q22/3 |
WinAMRX / S&P 36.78% / 20.54% |
LoseAMRX / S&P -4.71% / -0.46% |
WinAMRX / S&P 196.08% / -27.11% |
| 2020-Q10/3 |
LoseAMRX / S&P -27.80% / -19.60% |
LoseAMRX / S&P -8.46% / 3.47% |
LoseAMRX / S&P AMRX unavailable / -14.75% |
| 2019-Q41/3 |
WinAMRX / S&P 66.21% / 9.07% |
LoseAMRX / S&P -2.20% / 5.36% |
LoseAMRX / S&P AMRX unavailable / 2.99% |
| 2019-Q31/3 |
LoseAMRX / S&P -59.55% / 1.70% |
WinAMRX / S&P 18.35% / 5.02% |
LoseAMRX / S&P AMRX unavailable / 0.21% |
| 2019-Q21/3 |
LoseAMRX / S&P -49.40% / 4.30% |
WinAMRX / S&P 47.51% / 6.64% |
LoseAMRX / S&P AMRX unavailable / 8.65% |
| 2019-Q11/3 |
LoseAMRX / S&P 4.73% / 13.65% |
WinAMRX / S&P 69.31% / 8.12% |
LoseAMRX / S&P AMRX unavailable / 14.29% |
| 2018-Q40/3 |
LoseAMRX / S&P -39.03% / -13.52% |
LoseAMRX / S&P AMRX unavailable / 9.05% |
LoseAMRX / S&P AMRX unavailable / 18.23% |
| 2018-Q31/3 |
WinAMRX / S&P 35.22% / 7.71% |
LoseAMRX / S&P AMRX unavailable / 10.21% |
LoseAMRX / S&P AMRX unavailable / 19.06% |
| 2018-Q20/3 |
LoseAMRX / S&P AMRX unavailable / 3.43% |
LoseAMRX / S&P AMRX unavailable / 9.03% |
LoseAMRX / S&P AMRX unavailable / 14.46% |
| 2018-Q10/3 |
LoseAMRX / S&P AMRX unavailable / -0.76% |
LoseAMRX / S&P AMRX unavailable / 7.68% |
LoseAMRX / S&P AMRX unavailable / 12.46% |
| 2017-Q40/3 |
LoseAMRX / S&P AMRX unavailable / 6.64% |
LoseAMRX / S&P AMRX unavailable / 7.03% |
LoseAMRX / S&P AMRX unavailable / 13.82% |
| 2017-Q30/3 |
LoseAMRX / S&P AMRX unavailable / 4.48% |
LoseAMRX / S&P AMRX unavailable / 5.68% |
LoseAMRX / S&P AMRX unavailable / 17.57% |
| 2017-Q20/3 |
LoseAMRX / S&P AMRX unavailable / 3.09% |
LoseAMRX / S&P AMRX unavailable / 4.83% |
LoseAMRX / S&P AMRX unavailable / 17.74% |
| 2017-Q10/3 |
LoseAMRX / S&P AMRX unavailable / 6.07% |
LoseAMRX / S&P AMRX unavailable / 3.67% |
LoseAMRX / S&P AMRX unavailable / 13.32% |
| 2016-Q40/3 |
LoseAMRX / S&P AMRX unavailable / 3.82% |
LoseAMRX / S&P AMRX unavailable / 2.09% |
LoseAMRX / S&P AMRX unavailable / 7.05% |
| 2016-Q30/3 |
LoseAMRX / S&P AMRX unavailable / 3.85% |
LoseAMRX / S&P AMRX unavailable / 0.20% |
LoseAMRX / S&P AMRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AMRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 88.39% | 20.78% |
| Annualized return | 88.39% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AMRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 232.29% | 83.14% |
| Annualized return | 27.15% | 12.86% |
10Y · 2018-05-07 to 2026-08-27
| Metric | AMRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 19.99% | 319.30% |
| Annualized return | 1.84% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |